Objective:
Developing an unbiased and data-driven method to systematically approach generation of A9 dopaminergic neurons using HD-DoE^® technology in a reasonable timeframe and budget.

Why A9 Dopaminergic Neurons?Parkinson’s Disease (PD) affected over 8.5 million people in 2019 alone and has the fastest-growing population of affected individuals of any neurological disorder (WHO). PD is characterized by the loss of the A9 subset of Dopaminergic Neurons (DN). While efforts have been made using mouse models to identify drugs and test cell therapies involving brain tissue grafts, one major barrier to this has been the lack of available DNs for drug discovery screening.